Safety and feasibility of a tolerogenic dendritic cell-based treatment of multiple sclerosis (MS): a collaborative initiative comparing intranodal and intradermal cell administration in two phase I clinical trials

This work was supported by the Methusalem Funding Program from the University of Antwerp, by an applied biomedical research project of the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT-TBM 140191), project PI14/01811, integrated in the Plan Nacional de I+D+I and co-supported by the ISCIII-Subdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER), Instituto de Salud Carlos III from Spain, Convocatoria AES 2016 and by the Belgian Charcot Foundation. Furthermore, the authors received funding from the European Union's Horizon 2020 research and innovation program under grant agreement number 779316.